Cerity Partners LLC Neurocrine Biosciences Inc Transaction History

Cerity Partners LLC

$45.5 Billion
Q4 2024

A detailed history of Cerity Partners LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Cerity Partners LLC holds 41,737 shares of NBIX stock, worth $4.97 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

41,737

Previous 39,024 6.95%

Holding current value

$4.97 Million

Previous $4.49 Million 26.83%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$111.62 - $139.44 $302,825 - $378,300	2,713 Added 6.95%	41,737 $5.7 Million
Q3 2024 Nov 12, 2024	BUY	$114.58 - $153.15 $1.33 Million - $1.78 Million	11,622 Added 42.41%	39,024 $4.49 Million
Q2 2024 Aug 13, 2024	SELL	$130.86 - $143.19 $177,184 - $193,879	-1,354 Reduced 4.71%	27,402 $3.77 Million
Q1 2024 May 14, 2024	BUY	$130.4 - $143.74 $3.18 Million - $3.51 Million	24,392 Added 558.94%	28,756 $3.97 Million
Q4 2023 Jan 26, 2024	BUY	$106.07 - $132.76 $462,889 - $579,364	4,364 New	4,364 $575,000
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $32,678 - $38,277	365 Added 9.48%	4,214 $397,000
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $57,407 - $75,042	610 Added 18.83%	3,849 $389,000
Q4 2022 Feb 15, 2023	BUY	$106.72 - $127.06 $56,881 - $67,722	533 Added 19.7%	3,239 $386,000
Q3 2022 Nov 10, 2022	SELL	$92.03 - $107.81 $18,590 - $21,777	-202 Reduced 6.95%	2,706 $288,000
Q2 2022 Aug 10, 2022	BUY	$75.79 - $100.07 $220,397 - $291,003	2,908 New	2,908 $284,000

Others Institutions Holding NBIX

# of Institutions

654

Shares Held

96.5M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.4B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.

Account

Cerity Partners LLC Neurocrine Biosciences Inc Transaction History